{
    "relation": [
        [
            "Company",
            "COTT CORP Q\u2026",
            "AMEDISYS IN\u2026",
            "TEIJIN LTD\u2026",
            "INFINERA CO\u2026",
            "SKYWORKS SO\u2026"
        ],
        [
            "Symbol",
            "COT",
            "AMED",
            "TINLY",
            "INFN",
            "SWKS"
        ],
        [
            "Price",
            "11.09",
            "42.75",
            "37.78",
            "23.52",
            "96.76"
        ],
        [
            "%Chg",
            "+6.74%",
            "+3.94%",
            "+2.50%",
            "+2.31%",
            "+1.65%"
        ]
    ],
    "pageTitle": "BSX Progresses on TAVR Trial - October 11, 2012 - Zacks.com",
    "title": "",
    "url": "http://www.zacks.com/stock/news/84587/bsx-progresses-on-tavr-trial",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 2,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988048.90/warc/CC-MAIN-20150728002308-00218-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 857839215,
    "recordOffset": 857816830,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{63077=At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm., 14851=by Zacks Equity Research \u00a0\u00a0Published on October 11, 2012 |, 21342=Encouraged by positive results in the REPRISE I trial, Boston Scientific decided to evaluate the Lotus valve in a larger patient population. Enrollment in the study is expected to be completed in the first half of 2013. Patients with severe calcific aortic stenosis, aged 70 years or older, and those considered to be at high risk for surgery would be enrolled in the study., 63016=Copyright \u00a9 2015 Zacks Investment Research, 23422=During the last reported quarter, revenues from interventional cardiology (other than coronary stent systems) business increased 3% at constant currency to $209 million comprising US sales of $78 million and international sales of $131 million. Boston Scientific diversified the portfolio of this business with the acquisition of Atritech, also in 2011. This deal brought in the Watchman Left Atrial Appendage Closure device, which offers an alternative to anticoagulant drugs and is CE Mark approved. \u00a0The company is working to get the device approved in the US, possibly in 2013., 21760=The Lotus valve was inducted in Boston Scientific\u2019s portfolio following the acquisition of Sadra Medical in January 2011. Launch of the valve is expected in the second half of 2013, on the receipt of regulatory approval. At the end of the second quarter, the company noted that the cost to bring the Lotus valve to the market would be more than its earlier expectation.}",
    "lastModified": "Thu, 30 Jul 2015 22:09:25 -0500",
    "textBeforeTable": "Income Momentum Value Growth Zacks #1 Rank Top Movers for Jul 30, 2015 Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for 07/30/15 } } document.getElementById('score_val').className = ''; document.getElementById('score_val').innerHTML = ''; document.getElementById('tab_label').innerHTML = tab_text; { else } document.getElementById('score_val').className = 'scores_val'; document.getElementById('score_val').innerHTML = 'A'; document.getElementById('tab_label').innerHTML = tab_text+ ' Score'; { if(tab_text != 'income') document.getElementById('rank_text').innerHTML = cat_uri; var cat_uri = 'View All Zacks Rank #1 '+tab_text+' Stocks'; var cat_uri = '/stocks/buy-list/'+tab_text; { function footer_text(tab_text)",
    "textAfterTable": "Company Symbol Price %Chg ULTRA CLEAN\u2026 UCTT 7.64 +3.80% TESSCO TECH\u2026 TESS 24.44 +3.78% TRIUMPH BAN\u2026 TBK 13.82 +3.37% DUCOMMUN IN\u2026 DCO 24.01 +3.22% FIRST AMERI\u2026 FAF 40.77 +2.59% Company Symbol Price %Chg COTT CORP Q\u2026 COT 11.09 +6.74% AMEDISYS IN\u2026 AMED 42.75 +3.94% TEIJIN LTD\u2026 TINLY 37.78 +2.50% INFINERA CO\u2026 INFN 23.52",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}